UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16
Under the Securities Exchange Act of 1934

 

For the Month of December 2013

 

000-55041
(Commission File Number)

 

CAN-FITE BIOPHARMA LTD.

(Exact name of Registrant as specified in its charter)


10 Bareket Street
Kiryat Matalon, P.O. Box 7537
Petach-Tikva 4951778, Israel
(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover
Form 20-F or Form 40-F.

 

Form 20-F þ Form 40-F ¨

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by
Regulation S-T Rule 101(b)(1): ____

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by
Regulation S-T Rule 101(b)(7): ____

 

 
 

 

On December 31, 2013, Can-Fite BioPharma Ltd. issued a press release announcing that its subsidiary, OphthaliX Inc., will retrospectively analyze its Phase III dry eye syndrome study data to determine if there is a correlation between the A3 adenosine receptor biomarker and patients’ response to CF101. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

 

 
 

 

Exhibit Index

 

Exhibit No.

 

 

Description

 

99.1   Press Release, dated December 31, 2013

 

 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  Can-Fite BioPharma Ltd.  
     
Date:  December 31, 2013 By:

/s/ Motti Farbstein  

 
    Motti Farbstein  
    Chief Operating and Financial Officer